Artivion to Participate in Upcoming Investor Conferences
08/03/2022 - 08:25 AM
ATLANTA Aug. 3, 2022 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.
Artivion's management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 9:30 a.m. ET . A live webcast can be accessed through Artivion's website, www.artivion.com , on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
Members of the management team will also participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Monday, August 15, 2022 & Tuesday, August 16, 2022 . Due to the format of this event no webcast will be available.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia , Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com .
Contacts:
Artivion
Gilmartin Group LLC
D. Ashley Lee
Brian Johnston / Lynn Lewis
Executive Vice President &
Phone: 332-895-3222
Chief Financial Officer
investors@artivion.com
Phone: 770-419-3355
https://www.prnewswire.com/news-releases/artivion-to-participate-in-upcoming-investor-conferences-301598835.html
SOURCE Artivion, Inc.
AORT Rankings
#1241 Ranked by Stock Gains
AORT Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Country
US
City
Kennesaw
About AORT
cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica
